A Double-blind, Placebo-controlled Pilot Study of Citicoline add-on Therapy in Patients With Bipolar Disorder or Major Depressive Disorder and Amphetamine Abuse or Dependence
Overview
- Phase
- Not Applicable
- Intervention
- Citicoline
- Conditions
- Amphetamine Abuse
- Sponsor
- University of Texas Southwestern Medical Center
- Enrollment
- 60
- Locations
- 1
- Primary Endpoint
- Depression Symptoms
- Status
- Completed
- Last Updated
- 12 years ago
Overview
Brief Summary
Bipolar disorder (BD) is a common and severe psychiatric illness. Drug and alcohol abuse are very common in people with BD and other mood disorders and are associated with increased rates of hospitalization, violence towards self and others, medication non-adherence and cognitive impairment. However, few studies have investigated the treatment of dual-diagnosis patients as substance use is frequently an exclusion criterion in clinical trials of patients with BD. To address this need, we have developed a research program that explores the pharmacotherapy of people with BD and substance related-disorders. A potentially very interesting treatment for BD is citicoline. Some data suggest that this supplement may stabilize mood, decrease drug use and craving, and improve memory. We found promising results with citicoline in patients with BD and cocaine dependence. In recent years the use of amphetamine and methamphetamine has become an important public health concern. However, virtually no research has been conducted on the treatment of amphetamine abuse. We propose a double-blind placebo controlled prospective trial of citicoline in a group of 60 depressed outpatients with bipolar disorder, depressed phase or major depressive disorder and amphetamine abuse/dependence, to explore the safety and tolerability of citicoline, and its efficacy for mood symptoms, stimulant use and craving and its impact on cognition. Our goal is to determine which symptoms (e.g. mood, cognition, substance use) citicoline appears to be most effective and estimate effect sizes for future work.
Detailed Description
Sixty outpatients meeting the inclusion and exclusion criteria will be enrolled after completing an Institutional Review Board (IRB)-approved informed consent process. Baseline evaluation will include a medical and psychiatric history, structured clinical interview for Diagnostic and Statistical Manual (DSM-IV) (SCID), mood assessment with the Inventory of Depressive Symptomatology-Self Report (IDS-C), Young Mania Rating Scale (YMRS), and cognitive assessment with the Hopkins Auditory Verbal Learning Test (HVLT) (similar to the Rey Auditory Verbal Learning Test (RAVLT) but more alternative equivalent versions are available), Stroop and computer assessments including Sternberg Memory Task and the Running Memory Continuous Performance Test. Alternate but equivalent versions of all cognitive tests, except the Stroop, will be used to minimize practice effects with repeated administration. Days and amounts of amphetamine and other substance use will be assessed at each visit with urine drug screens, and through self-report using the timeline follow-back method. Amphetamine, and other drug, craving will be assessed with a visual analogue scales. Citicoline or placebo add-on therapy will be given beginning at one tablet (500mg)/day with an increase to two tablets 1000 mg/day at week 2, three tables 1500 mg/day at week 4 and four tablets 2000 mg/day at week 6.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Men and women ages 18-70 years
- •Meeting criteria for a current major depressive episode (bipolar I,II, not otherwise specified (NOS)
- •, depressed phase) or major depressive disorder on the Structured Clinical Interview for the Diagnostic and Statistical Manual for Mental Disorders (SCID) with a duration of at least 4 weeks
- •Meeting criteria for amphetamine abuse or dependence with use within 14 days prior to baseline
- •No psychotropic medication changes within 14 days prior to study entry
Exclusion Criteria
- •Pregnant or nursing women
- •Current citicoline therapy
- •Active suicidal or homicidal ideation with plan and intent
- •Dementia, mental retardation or other severe cognitive impairment that might interfere with the informed consent process
- •Currently incarcerated at a prison or jail
- •Severe or life threatening medical condition (e.g. terminal cancer, congestive heart failure)
Arms & Interventions
Citicoline
Citicoline is an over the counter supplement that may have neuroprotective properties and may have antidepressant effects.
Intervention: Citicoline
Placebo
Placebo matching active medication.
Intervention: Placebo
Outcomes
Primary Outcomes
Depression Symptoms
Time Frame: 12 weeks
Inventory of Depressive Symptomatology-Clinician Rated (IDS-C), (a clinician-administered depression scale) is used to assess the severity of depressive symptoms.Scores can range from 0 to 84. The higher the score, the worse the depressive symptoms(worse outcome).
Secondary Outcomes
- Amphetamine Craving(12 Weeks)
- Amphetamine Use(12 weeks)
- Hopkins Auditory Verbal Learning Test (HVLT)(12 weeks)
- Stroop Color Word Test(12 weeks)